844891-10-7

Basic information

• Product Name: TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE;BUTTPARK 99\06-05;4-(4-BROMOBENZYL)PIPERAZINE, N1-BOC PROTECTED;1-Boc- 4-(4-bromobenzyl)piperazine;4-(4-Bromobenzyl)piperazine,N1-BOCprotected95%
• CAS NO: 844891-10-7
• Molecular Formula: C₁₆H₂₃BrN₂O₂
• Molecular Weight: 355.27
• Mol File: 844891-10-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 69-72
• Boiling Point: 409°C at 760 mmHg
• Flash Point: 201.2°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 6.7E-07mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: Room temperature.
• CAS DataBase Reference: TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE(844891-10-7)
• EPA Substance Registry System: TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE(844891-10-7)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 844891-10-7(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE is a chemical compound with the molecular formula C17H24BrN3O2. It is a piperazine derivative that contains a tert-butyl group and a 4-bromobenzyl group attached to the piperazine ring. TERT-BUTYL 4-(4-BROMOBENZYL)PIPERAZINE-1-CARBOXYLATE is commonly used in the synthesis of pharmaceuticals and organic compounds. It may also have potential applications in medicinal chemistry and drug development due to its piperazine and carboxylate functionalities. Additionally, it is important to handle this compound with care and in accordance with proper safety protocols due to its potentially hazardous nature.

InChI:InChI=1/C16H23BrN2O2/c1-16(2,3)21-15(20)19-10-8-18(9-11-19)12-13-4-6-14(17)7-5-13/h4-7H,8-12H2,1-3H3

Upstream product

• 589-15-1 1-bromomethyl-4-bromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1264940-54-6 tert-butyl 4-{4-[4-(1-methyl-6-oxo-1,6-dihydro[4,4']bipyrimidinyl-2-yloxy)piperidin-1-yl]benzyl}piperazine-1-carboxylate 
• 936694-19-8 tert-butyl 4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperazine-1-carboxylate 
• 91345-62-9 1-(4-bromobenzyl)piperazine 
• 510725-48-1 1-(4-bromobenzyl)piperazine hydrochloride 

Relevant articles and documents

SYNTHESIS, CRYSTAL STRUCTURE, AND BIOLOGICAL EVALUATION OF (E)-1-(4-(4-BROMOBENZYL)PIPERAZIN-1-YL)- 3-(4-CHLOROPHENYL)PROP-2-EN-1-ONE

Abstract: Title compound (E)-1-(4-(4-bromobenzyl)piperazin-1-yl)-3-(4-chlorophenyl)prop-2-en-1-one (5) (C20H20BrClN2O, Mr?=?419.74) is designed, synthesized, and evaluated for its biological activity. Its structure is confirmed by FTIR, 1H and 13C NMR, HRMS, and X-ray single crystal diffraction. The structure is stabilized via inter- as well as intra- C–H…O interactions and intra hydrogen bonding C–H…N interactions. The Hirshfeld surface intermolecular interactions are studied using the crystal structure. The maximum surface area of the molecule is occupied by C–H…O interactions. In addition, the biological activity in vitro and in vivo of title compound 5 is also evaluated.

Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof

The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.

SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure provides hetero-biclyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.